Sintilimab is included in the guidelines of the Chinese Society of Clinical Oncology (CSCO) for the first-line treatment of five major tumor types

On April 23-24, 2022, the annual high-profile academic event in the oncology community, the Chinese Society of Clinical Oncology (CSCO) Guidelines Conference, was held online, and the new CSCO series of guidelines were released
.

New breakthrough in immunotherapy.
Sintilimab-based first-line immunotherapy was successfully included in the 2022 edition of the "CSCO Guidelines for Diagnosis and Treatment of Gastric Cancer", "CSCO Guidelines for Diagnosis and Treatment of Esophageal Cancer", "CSCO Guidelines for Diagnosis and Treatment of Primary Liver Cancer" and "CSCO Immune Examination" Recommendations of the Guidelines for the Clinical Application of Point Inhibitors
.

Together with the first-line treatment recommendations that have been included in the "CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer", the national first-line innovative drug sintilimab has achieved a breakthrough in the inclusion of the first-line treatment of five tumor types in the CSCO guidelines
.

CSCO guideline update: Sintilimab combined with chemotherapy for first-line treatment of advanced gastric cancer and advanced esophageal squamous cell carcinoma Based on the ORIENT-16 study, the first-line treatment of advanced gastric cancer is recommended to add "PD-L1 CPS ≥ 5, sintilimab combined with XELOX (class 1A evidence)"; for class II, "PD-L1 CPS < 5 or Detection is not available, sintilimab in combination with XELOX (category 1B)”
.

"CSCO Guidelines for the Diagnosis and Treatment of Esophageal Cancer (2022 Edition)": Based on the ORIENT-15 study, "sintilimab combined with chemotherapy (class IA evidence)" is newly recommended for first-line treatment of advanced esophageal cancer
.

CSCO guideline update: Sintilimab combined with bevacizumab for first-line treatment of advanced hepatocellular carcinoma into primary liver cancer "Sintilimab combined with bevacizumab (category 1A evidence)" has been added to the Class I recommendation for first-line treatment of hepatocellular carcinoma
.

Prior to this, sintilimab has been successfully included in the CSCO guidelines for first-line treatment of non-squamous non-small cell lung cancer (NSCLC), squamous NSCLC, and hepatocellular carcinoma
.

This time, sintilimab achieved a breakthrough that the first-line treatment of five tumor types was included in the CSCO guidelines
.

As an authoritative and universal guideline with Chinese characteristics in the domestic oncology field, the Chinese Society of Clinical Oncology (CSCO) guideline is formulated based on high-quality international evidence-based evidence, and fully considers China's national conditions.
Research evidence is of great value and plays an important role in regulating the diagnosis and treatment of oncology clinicians in China and guiding clinical practice
.

In this CSCO guideline update, "sintilimab combined with chemotherapy" is listed as the first-line treatment regimen for advanced gastric cancer and advanced esophageal squamous cell carcinoma, which will change the systemic treatment pattern of gastric and esophageal cancer in China
.

From the update of the guidelines for the diagnosis and treatment of primary liver cancer, it can be seen that in the first-line systemic anti-tumor therapy, combined immunotherapy has also received a high-level recommendation
.

The CSCO guidelines will provide important guidance for oncologists to apply immunocombination therapy in clinical practice
.

About Sintilimab Sintilimab, whose trade name is Daboshu® (sintilimab injection) in China, is an innovative PD- 1 inhibitor drugs
.

Sintilimab is a human immunoglobulin G4 (IgG4) monoclonal antibody that specifically binds to the PD-1 molecule on the surface of T cells, thereby blocking PD-1/programmed death receptors that lead to tumor immune tolerance.
The Programmed Death-Ligand 1 (PD-L1) pathway reactivates the anti-tumor activity of lymphocytes, thereby achieving the goal of treating tumors
.

More than two dozen clinical studies (of which more than 10 are registration clinical trials) are currently underway to evaluate the antitumor effect of sintilimab in various solid tumors and hematological tumors
.

Sintilimab has been approved in China for four indications and has been successfully included in China's National Medical Insurance List, including: For the treatment of relapsed or refractory classical Hodgkin lymphoma after at least second-line systemic chemotherapy; in combination with pemetrexed Citrus and platinum-based chemotherapy for first-line treatment of EGFR- or ALK-negative unresectable locally advanced or metastatic non-squamous NSCLC; combination gemcitabine and platinum-based chemotherapy for unresectable locally advanced or metastatic squamous NSCLC First-line therapy; in combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma not previously treated with systemic therapy
.

In addition, the marketing application of sintilimab has been accepted and reviewed by the China National Medical Products Administration (NMPA) for three indications, including: Combination of cisplatin and paclitaxel/cisplatin and 5-fluorouracil for advanced or metastatic esophageal squamous First-line treatment of cancer; first-line treatment of unresectable locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with oxaliplatin and capecitabine; epidermal growth factor in combination with bevacizumab and chemotherapy Receptor tyrosine kinase inhibitor (EGFR-TKI) therapy failure in EGFR-mutant non-squamous non-small cell lung cancer
.